Skip to main content
. 2023 Sep 11;16:17562848231197923. doi: 10.1177/17562848231197923

Table 4.

Specification of discontinuation in retransitioned patients.

Infliximab discontinuation Retransitioned due to objective markers (n = 4) Retransitioned due to symptoms only (n = 9)
Discontinuing infliximab with switch to other biological treatment 1 (25.0%) 4 (44.5%)
Discontinuing infliximab without switch 3 (75.0%) 5 (55.5%)